Black race and distant recurrence after neoadjuvant or adjuvant chemotherapy in breast cancer
- PMID: 30136072
- PMCID: PMC6202136
- DOI: 10.1007/s10585-018-9932-8
Black race and distant recurrence after neoadjuvant or adjuvant chemotherapy in breast cancer
Abstract
Black race compared to white race is associated with more advanced stage and biologically aggressive breast cancer. Consequently, black patients are more frequently treated with neoadjuvant chemotherapy (NAC) than white patients. However, it is unclear how distant recurrence-free survival (DRFS) of black patients treated with NAC, compares to DRFS of black patients treated with adjuvant chemotherapy (AC). We evaluated the association between race, distant recurrence, and type of chemotherapy (AC or NAC) in localized or locally advanced breast cancer. We evaluated DRFS in 807 patients, including 473 black, 252 white, 56 Hispanic, and 26 women of other or mixed race. The association between AC or NAC and DRFS was examined using multivariate Cox proportional hazard models that included race, age, stage, estrogen receptor (ER) and triple negative (TN) status. When the black and white subjects were pooled for the analysis the features associated with worse DRFS included stage III disease and age < 50 years, but not ER-negative disease, TN disease, the use of NAC, or black race. However, in the analysis stratified by race NAC was associated with worse DRFS compared to AC in black (HR 2.70; 95% CI 1.73-4.22; p < 0.0001), but not in white women (HR 1.29, 95% CI 0.56-2.95; p = 0.36). Black patients treated with NAC had worse DRFS than black patients treated with AC, or white patients treated with either NAC or AC. These findings need to be validated in a large-scale observational study and the effect of NAC on the breast cancer microenvironment in black women needs to be further evaluated.
Keywords: Adjuvant chemotherapy; Black patients; Breast cancer; Distant recurrence; Neoadjuvant chemotherapy.
Conflict of interest statement
Figures


Similar articles
-
Racial disparity in distant recurrence-free survival in patients with localized breast cancer: A pooled analysis of National Surgical Adjuvant Breast and Bowel Project trials.Cancer. 2022 Jul 15;128(14):2728-2735. doi: 10.1002/cncr.34241. Epub 2022 May 17. Cancer. 2022. PMID: 35578919 Free PMC article.
-
Race and recurrence in women who undergo neoadjuvant chemotherapy for breast cancer.Am J Surg. 2013 Apr;205(4):397-401. doi: 10.1016/j.amjsurg.2013.01.009. Epub 2013 Feb 16. Am J Surg. 2013. PMID: 23422317
-
Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.JAMA Netw Open. 2023 Dec 1;6(12):e2349646. doi: 10.1001/jamanetworkopen.2023.49646. JAMA Netw Open. 2023. PMID: 38153734 Free PMC article.
-
Proposing a novel molecular subtyping scheme for predicting distant recurrence-free survival in breast cancer post-neoadjuvant chemotherapy with close correlation to metabolism and senescence.Front Endocrinol (Lausanne). 2023 Oct 12;14:1265520. doi: 10.3389/fendo.2023.1265520. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37900131 Free PMC article. Review.
-
Breast Cancer Outcomes of Neoadjuvant Versus Adjuvant Chemotherapy by Receptor Subtype: A Scoping Review.J Surg Res. 2020 Oct;254:83-90. doi: 10.1016/j.jss.2020.04.011. Epub 2020 May 15. J Surg Res. 2020. PMID: 32422430 Free PMC article.
Cited by
-
The pro-tumorigenic host response to cancer therapies.Nat Rev Cancer. 2019 Dec;19(12):667-685. doi: 10.1038/s41568-019-0209-6. Epub 2019 Oct 23. Nat Rev Cancer. 2019. PMID: 31645711 Review.
-
Chemotherapy-Induced Metastasis: Molecular Mechanisms, Clinical Manifestations, Therapeutic Interventions.Cancer Res. 2019 Sep 15;79(18):4567-4576. doi: 10.1158/0008-5472.CAN-19-1147. Epub 2019 Aug 20. Cancer Res. 2019. PMID: 31431464 Free PMC article. Review.
-
Gynecologic Care of Black Breast Cancer Survivors.Curr Breast Cancer Rep. 2024 Mar;16(1):84-97. doi: 10.1007/s12609-024-00527-4. Epub 2024 Feb 19. Curr Breast Cancer Rep. 2024. PMID: 38725438 Free PMC article.
-
Macrophages in tumor cell migration and metastasis.Front Immunol. 2024 Nov 1;15:1494462. doi: 10.3389/fimmu.2024.1494462. eCollection 2024. Front Immunol. 2024. PMID: 39555068 Free PMC article. Review.
-
The Contribution of Race to Breast Tumor Microenvironment Composition and Disease Progression.Front Oncol. 2020 Jun 30;10:1022. doi: 10.3389/fonc.2020.01022. eCollection 2020. Front Oncol. 2020. PMID: 32714862 Free PMC article. Review.
References
-
- N H, AM N, M K, D M, K B, CL K, M Y, J R, Z T, A M, DR L, HS C, EJ F, KA C (2017) SEER Cancer Statistics Review, 1975–2014, National Cancer Institute; Bethesda, MD.
-
- Eley JW, Hill HA, Chen VW, Austin DF, Wesley MN, Muss HB, Greenberg RS, Coates RJ, Correa P, Redmond CK, et al. (1994) Racial differences in survival from breast cancer. Results of the National Cancer Institute Black/White Cancer Survival Study. JAMA 272 (12):947–954 - PubMed
-
- Li CI, Malone KE, Daling JR (2002) Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev 11 (7):601–607 - PubMed
-
- Elledge RM, Clark GM, Chamness GC, Osborne CK (1994) Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. Journal of the National Cancer Institute 86 (9):705–712 - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical